Skip to main content

Table 1 Demographic and clinical data of patients with and without foot and/or ankle arthritis

From: Prevalence of feet and ankle arthritis and their impact on clinical indices in patients with rheumatoid arthritis: a cross-sectional study

  With FAA Without FAA P-values
(598, 29.2%) (1448, 70.8%)
Demographic Characteristics
 Female, n (%) 520 (87.0) 1209 (83.5) 0.05
 Age at the time of enrollment, years 54.1 ± 12.6 54.4 ± 13.0 0.63
 Disease duration, years 8.5 ± 8.3 7.4 ± 7.0 < 0.01
  Disease duration < 1 year, n (%) 99 (16.6) 228 (15.8) 0.69
  Disease duration < 2 years, n (%) 170 (28.5) 399 (27.7) 0.70
  Disease duration < 3 years, n (%) 200 (33.6) 509 (35.3) 0.47
  Disease duration < 4 years, n (%) 241 (40.4) 622 (43.1) 0.28
  Disease duration < 5 years, n (%) 273 (45.8) 71 (49.6)  
  Disease duration ≥5 years, n (%) 323 (54.2) 727 (50.4) 0.12
 Body mass index, kg/m2 22.6 ± 3.6 22.6 ± 3.2 0.97
 Current/ex-smoker, n (%) 89 (14.9) 217 (15.0) 1.00
 Presence of RA-associated lung diseases, n (%) 21 (3.5) 47 (3.3) 0.79
 Positive for rheumatoid factor, n (%) 491 (85.1) 1174 (83.5) 0.38
 Positive for anti-cyclic citrullinated peptide, n (%) 404 (84.7) 1046 (85.1) 0.88
Radiographic damage
 Hand X-ray    
  Erosion, n (%) 197 (40.0) 417 (34.8) < 0.05
  Joint space narrowing, n (%) 226 (45.8) 555 (46.5) 0.83
 Feet X-ray
  Erosion, n (%) 153 (36.7) 247 (29.1) < 0.01
  Joint space narrowing, n (%) 107 (25.7) 224 (26.5) 0.79
Medication
 Current glucocorticoid use, n (%) 497 (83.1) 1169 (80.7) 0.21
 Daily dose (prednisolone equivalent), mg 5.2 ± 10.7 4.3 ± 4.2 < 0.01
 Current use of MTX, n (%) 567 (94.8) 1337 (92.3) 0.05
 Previous use of bDMARDs, n (%) 145 (24.2) 233 (16.1) < 0.01
Disease activity
 Swollen joint count (44 joints examined) 8.9 ± 6.8 3.9 ± 4.4 < 0.01
 Tender joint count (44 joints examined) 11.9 ± 8.6 4.9 ± 5.0 < 0.01
 Patients Global Assessment score (1–10 mm) 6.7 ± 2.3 5.7 ± 2.6 < 0.01
 Evaluator’s Global Assessment score (1–10 mm) 6.0 ± 5.2 5.2 ± 2.6 < 0.01
 ESR, mm/h 48.8 ± 29.2 41.3 ± 27.2 < 0.01
 CRP, mg/dL 2.6 ± 3.3 1.7 ± 2.3 < 0.01
 DAS28-ESR score 5.6 ± 1.4 4.7 ± 1.5 < 0.01
 DAS28-CRP score 4.9 ± 1.4 4.0 ± 1.5 < 0.01
 SDAI score 30.3 ± 14.3 21.3 ± 12.8 < 0.01
 CDAI score 27.8 ± 13.2 19.7 ± 11.9 < 0.01
 RAPID3 score 15.9 ± 6.0 12.4 ± 6.6 < 0.01
The proportion of patients with remission
 DAS28-ESR, n (%) 21 (3.5) 153 (10.7) < 0.01
 DAS28-CRP, n (%) 38 (6.4) 305 (21.4) < 0.01
 SDAI, n (%) 8 (1.3) 112 (7.7) < 0.01
 CDAI, n (%) 3 (0.5) 69 (4.8) < 0.01
 RAPID3, n (%) 12 (2.0) 128 (8.9) < 0.01
 Boolean-based criteria, n (%) 5 (0.8) 82 (5.8) < 0.01